EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. (Nasdaq: ENMD), today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer."  Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

The study will be open at Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center, all of whom are members of the Dana-Farber/Harvard Cancer Center.  The DF/HCC hospitals join Princess Margaret Hospital in Toronto as a clinical trial site.  Additional participants are expected to be added later this quarter.    

The primary objective of the study will be to determine the progression free survival (PFS) rate of patients at six months. Patients with platinum resistant ovarian, fallopian or peritoneal cancer enrolled in the study will receive ENMD-2076 administered orally as a single agent once a day in 28-day cycles.  A total of 60 patients are expected to be enrolled in the study.  

"We are very excited to participate in the Phase 2 study of ENMD-2076 in recurrent ovarian cancer," said Dr. Matulonis.  "It will be particularly interesting to determine the compound's potential in this difficult to treat patient population."

Carolyn F. Sidor, M.D., M.B.A., EntreMed Vice President and Chief Medical Officer commented on the site initiation, "We are pleased to have Dr. Matulonis and the physicians at DF/HCC participate in this Phase 2 study with ENMD-2076.  DF/HCC is one of the two institutions who are participating in the Phase 1 study of ENMD-2076 in patients with various solid tumors, and we are delighted that the collaboration continues into Phase 2."